Details for New Drug Application (NDA): 214697
✉ Email this page to a colleague
The generic ingredient in NEFFY is epinephrine. There are twenty-one drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the epinephrine profile page.
Summary for 214697
| Tradename: | NEFFY |
| Applicant: | Ars Pharms Operation |
| Ingredient: | epinephrine |
| Patents: | 8 |
Pharmacology for NDA: 214697
| Mechanism of Action | Adrenergic alpha-Agonists Adrenergic beta-Agonists |
Medical Subject Heading (MeSH) Categories for 214697
Suppliers and Packaging for NDA: 214697
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| NEFFY | epinephrine | SPRAY;NASAL | 214697 | NDA | Medical Purchasing Solutions, LLC | 71872-7330 | 71872-7330-1 | 1 BLISTER PACK in 1 BAG (71872-7330-1) / 1 VIAL, SINGLE-DOSE in 1 BLISTER PACK / 100 uL in 1 VIAL, SINGLE-DOSE |
| NEFFY | epinephrine | SPRAY;NASAL | 214697 | NDA | ARS Pharmaceuticals Operations, Inc. | 82580-010 | 82580-010-02 | 2 BLISTER PACK in 1 CARTON (82580-010-02) / 1 VIAL, SINGLE-DOSE in 1 BLISTER PACK / 100 uL in 1 VIAL, SINGLE-DOSE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SPRAY;NASAL | Strength | 2MG/SPRAY | ||||
| Approval Date: | Aug 9, 2024 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Feb 6, 2038 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Feb 6, 2039 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | NASAL ADMINISTRATION OF EPINEPHRINE FOR THE TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS | ||||||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Feb 6, 2038 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | NASAL ADMINISTRATION OF EPINEPHRINE FOR THE TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS | ||||||||
Complete Access Available with Subscription
